ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSalma Health, Inc.

About this trial

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Eligibility criteria

Qualifiers

Adults (≥18 years) of any gender identity presenting for care with a depressed mood.

Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care.

Able to provide informed consent and comply with all study requirements.

Disqualifiers

Any condition deemed by the investigator to preclude safe participation in study assessments.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

5,000 Participants
are grouped into 3 trial groups

Sponsors and collaborators

Salma Health, Inc.

Lead sponsor

Center for Neurohealth, Inc

Collaborator